VEGFA antibody [A7-E11-G2]
GTX16027
ApplicationsImmunoFluorescence, Western Blot, ELISA, ImmunoCytoChemistry
Product group Antibodies
ReactivityHuman
TargetVEGFA
Overview
- SupplierGeneTex
- Product NameVEGF antibody [A7-E11-G2]
- Delivery Days Customer9
- Antibody SpecificityThe mouse anti-human VEGF antibody specifically detects targets derived from human recombinant protein at various concentrations. Cross reactivity with mouse and rat are expected from sequence similarity.
- Application Supplier NoteWe recommend the following starting dilutions: For ELISA: Use at a concentration of 6.25 ng/ml. For WB: Use at a dilution of 1:2000. Optimal dilutions should be determined experimentally by the end user.
- ApplicationsImmunoFluorescence, Western Blot, ELISA, ImmunoCytoChemistry
- CertificationResearch Use Only
- ClonalityMonoclonal
- Clone IDA7-E11-G2
- Concentration1 mg/ml
- ConjugateUnconjugated
- Gene ID7422
- Target nameVEGFA
- Target descriptionvascular endothelial growth factor A
- Target synonymsMVCD1; vascular endothelial growth factor A; vascular endothelial growth factor A121; vascular endothelial growth factor A165; vascular permeability factor; VEGF; VPF
- HostMouse
- IsotypeIgG
- Protein IDP15692
- Protein NameVascular endothelial growth factor A
- Scientific DescriptionThis gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. [provided by RefSeq, Nov 2015]
- ReactivityHuman
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- The c.1085A>G Genetic Variant of CSF1R Gene Regulates Tumor Immunity by Altering the Proliferation, Polarization, and Function of Macrophages. Yeh YM et al., 2017 Oct 15, Clin Cancer ResRead more